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The induction of broadly neutralizing antibodies (bNAbs) is a major goal in the development of an
effective vaccine against HIV-1. A soluble, trimeric, germline (gI) bNAb-targeting variant of the HIV-1
envelope glycoprotein (termed BG505 SOSIP.v4.1-GT1.1 gp140, abbreviated to GT1.1) has recently been
developed. Here, we have compared this new immunogen with the parental trimer from which it was
derived, BG505 SOSIP.664 gp140. We used a comprehensive suite of biochemical and biophysical
methods to determine physicochemical similarities and differences between the 2 trimers, and thereby
assessed whether additional formulation development efforts were needed for the GT1.1 vaccine
candidate. The overall higher order structure and oligomeric states of the 2 vaccine antigens were quite
similar, as were their thermal, chemical, and colloidal stability profiles, as evaluated during accelerated
stability studies. Overall, we conclude that the primary sequence changes made to create the gl bNAb-
targeting GT1.1 trimer did not detrimentally affect its physicochemical properties or stability profiles
from a pharmaceutical perspective. This developability assessment of the BG505 GT1.1 vaccine antigen
supports using the formulation and storage conditions previously identified for the parental SOSIP.664
trimer and enables the development of GT1.1 for phase I clinical studies.
© 2019 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Envelope glycoproteins (Env) have been a focus of HIV-1 vaccine
research for over 30 years.1 Because Env spikes are the only virus-
encoded antigen exposed on the viral surface, they are the only
relevant targets for broadly neutralizing antibodies (bNAbs). Thefrom the authors by request
19.01.033.
63 5451) and David B. Volkin
y@iavi.org (A.K. Dey).
Inc. on behalf of the American PhaEnv spike is composed of a trimer of noncovalently linked gp120
and gp41 glycoprotein heterodimers. The soluble BG505 SOSIP.664
gp140 trimer adopts a native-like conformation and presents most
of the known bNAb epitope clusters.2,3 When tested as an immu-
nogen in several animal models, this trimer elicits neutralizing
antibodies (NAbs) to the neutralization-resistant (Tier-2) autolo-
gous BG505.T332N virus.4 A soluble, stable, variant trimer termed
BG505 SOSIP.664 gp140 has been manufactured under cGMP con-
ditions for evaluation in phase I clinical trials.5 To support the cGMP
manufacture of this trimer, analytical characterization and formu-
lation development experiments were performed to identify con-
ditions that will not only ensure stability of the protein drugrmacists Association®. This is an open access article under the CC BY license (http://
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that will be used in clinical studies.
An effective HIV-1 Env vaccine will need to induce a more
broadly active set of NAbs that could protect against multiple HIV-1
strains, which remains a highly challenging task. One plausible
approach involves using an immunogen that targets the human
germline (gl) precursors for bNAbs, followed by maturation of the
initiated antibody lineage(s) by the use of one or more Env im-
munogens.6-11 To explore this concept, a variant of the BG505
SOSIP.664 gp140 trimer was developed that, in vitro, can engage the
gl-precursors of bNAbs that target the trimer apex and the CD4-
binding site.11 The new trimer, BG505 SOSIP.v4.1-GT1.1 gp140
(abbreviated to GT1.1), was created from the parental SOSIP.664
trimer by introducing 18 amino acid substitutions and a 7-residue
deletion into the V2 loop, resulting in the removal of 5 glycosyla-
tion sites.11 Despite these changes, the GT1.1 trimer retains the
native-like conformation adopted by its parental molecule.11
As we plan to advance the GT1.1 trimer to early clinical devel-
opment, we wanted to perform an early developability assessment
to understand (1) formulation risks (and whether additional
formulation development efforts are needed to produce a stable
vaccine dosage form to facilitate rapid initiation of clinical evalua-
tions), and (2) comparative physicochemical properties of GT1.1
trimer, in relation to the parental SOSIP.664 trimer, to evaluate the
similarities and difference when formulated in the same (parental
trimer) formulation condition. Thus, this work is a case study of
evaluating the formulation/stability risk with a new complex
protein-based HIV Env vaccine candidate by comparison to a
closely related, yet molecularly distinct, HIV Env trimer antigen.
Although developability assessments are commonly performed for
selection of optimal molecular versions of a new monoclonal
antibody drug candidate in terms of improved pharmaceutical
properties (with similar biological properties12), this type of eval-
uation has not been as widely applied to new recombinant protein
antigens during early vaccine development.
To this end, the biophysical and biochemical properties of both
the SOSIP.664 and GT1.1 recombinant protein trimeric antigens
have been systematically evaluated using a set of orthogonal
physicochemical techniques that address key aspects of the struc-
tural integrity of both molecules. In addition, the conformational,
chemical and colloidal stability profiles of both trimers were also
evaluated and compared in the currently used formulation buffer
for frozen liquid storage of the SOSIP.664 antigen. The prototypic
BG505 SOSIP.664 trimer was first analyzed using a larger set of
biophysical and biochemical methods. The resulting information
allowed for down-selection of the most suitable procedures to
apply to the GT1.1 trimer, which was only available in smaller
quantities at this stage of the development process. Some of these
methods have been used previously for analytical characterization
and cGMP quality control analyses for SOSIP.664 gp14013,14. Overall,
we conclude that the primary sequence changes made to create the
gl bNAb-targeting GT1.1 trimer did not detrimentally affect its
physicochemical properties or stability profiles from a pharma-
ceutical perspective. Hence, the new GT1.1 vaccine antigen can be
formulated and stored as frozen liquid dosage form under the
conditions previously defined for the parental BG505 SOSIP.664
trimer,5 a finding that helps facilitate more rapid advancement of
the new GT1.1 vaccine antigen into initial clinical development.
Materials and Methods
Materials
A frozen stock of BG505 SOSIP.664 gp140 trimers produced in
stable CHO cells and purified by a series of column steps andformulated at a concentration of 3 mg/mL in “Formulation Buffer”
(20 mM Tris, 100 mMNaCl pH 7.5)5 was supplied by KBI Biopharma
Inc. The BG505 SOSIP.v4.1-GT1.1 trimer (GT1.1) is amodified version
of BG505 SOSIP.664, engineered to engage germline antibody pre-
cursors, achieved by substitution of 18 amino acids (resulting in the
removal of 5 potential N-glycan sites) and deletion of 7 amino acids
in the V2 loop.15 The GT1.1 trimers were produced in stable CHO
cells at the Weill Cornell Medical College, purified by the same
method and supplied frozen at a concentration of 0.5 mg/mL in the
same buffer. To use in method development (sedimentation ve-
locity analytical ultracentrifugation [SV-AUC], size-exclusion chro-
matography [SEC], etc.), a 250-mg aliquot of CHO celleexpressed
BG505 SOSIP.664 gp140 monomers (i.e., one protomer of the
trimer) was collected from a 2G12-immunoaffinity and SEC column
purification at the Weill Cornell Medical College. Sodium chloride
was purchased from Fisher Scientific (Hampton, NH). Sucrose,
trehalose from Pfanstiehl Laboratories (Waukegan, Illinois), and
sulfobutyl-b-cyclodextrin from Captisol (San Diego, CA). All other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO).Methods
Sample Preparation
Before analysis, BG505 SOSIP.664 and GT1.1 gp140 trimer sam-
ples were thawed at room temperature and diluted in “Formulation
Buffer” (see the aforementioned) to the desired concentration.
Because the pH of Tris-buffered solutions is temperature-
dependent, for some techniques described in the following
(specifically, those that include a thermal melt), the trimers were
dialyzed into PBS buffer (20 mM NaH2PO4, 100 mM NaCl pH 7.5)
overnight at 4C before use.UV-Visible Spectroscopy
The UV-visible absorption spectra of the SOSIP.664 and GT1.1
trimers were recorded with an Agilent 8453 UV-visible spectro-
photometer (Palo Alto, CA). The concentration of each protein was
calculated based on the calculated16 extinction coefficients 1.590 g/
L at 280 nm for SOSIP.664 and 1.559 g/L at 280 nm for GT1.1.
Samples were assayed before and after centrifugation (5000 rpm
for 5 min). Spectra were corrected for light scattering using a
technique included in the manufacturer’s data analysis software
(ChemStation UV-Vis analysis software, Agilent Technologies).
Second derivative analysis was performed using Origin (OriginLab,
Northampton, MA).SDS-PAGE and BN-PAGE
BG505 SOSIP.664 and GT1.1 samples were mixed with 4X
NuPAGE LDS sample buffer (Thermo Fisher Scientific) with and
without 5 mM dithiothreitol (Thermo Fisher Scientific) and incu-
bated at 95C for 5 min. Samples were then treated with 10 mM
iodoacetamide (Thermo Fisher Scientific) at 25C in the dark for
30min. Approximately, 10 mg of each sample were separated on 4%-
12% Bis-Tris gels using NuPAGE MOPS SDS Running Buffer (Thermo
Fisher Scientific). SeeBlue Plus2 Pre-Stained Protein Standard
(Thermo Fisher Scientific) was used as a molecular weight (MW)
ladder. BN-PAGEwas performedwith the same system used in SDS-
PAGE. For Blue-Native gels, samples were mixed with NativePAGE
Sample Buffer (Thermo Fisher Scientific) and were separated on
NativePAGE Bis-Tris 3%-12% Mini Gels using NativeMark Unstained
Protein Standard (Thermo Fisher Scientific) as a MW marker. Pro-
tein bands on all gels were visualized by staining with Bio-safe
Coomassie Blue G250 stain (Bio-Rad Laboratories, Hercules, CA)
or by silver staining.
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Samples were prepared by drying 80 mg of protein using a
SpeedVac (Eppendorf, Hamburg, Germany), followed by resus-
pensionwith 250mM Tris, 6M guanidine HCl, pH 7.5, and reduction
with 50 mg/mL DTT (55C for 20 min). The samples were then
alkylated with 50 mM iodoacetamide for 30 min at room temper-
ature in the dark, before addition of 180 mL of 50mMTris pH 7.5 and
2 mL of PNGase F (Promega, Madison, WI) and incubation of the
mixture overnight at 37C. The following morning, either a trypsin/
LysC mixture (Promega) or chymotrypsin (Promega) was added,
and the samples were incubated for 4 h at 37C. Trifluoroacetic acid
(TFA, 0.5%) was added to quench the proteolysis reaction, and 50 mL
of the digested protein solution was subjected to liquid
chromatographyemass spectrometry (LC-MS), as follows.
The peptides from the digested protein solution were separated
by a liquid chromatography system (Thermo Fisher Scientific)
before analysis. Peptides were injected onto a C18 column (1.7 mm,
2.1 150mm,Waters Corporation, Milford, MA) and a 90min 0.5%-
41% B gradient (A: H2O and 0.05% TFA; B: acetonitrile and 0.04%
TFA; 200 mL/min flow rate) was used for separation. Mass spec-
trometry (MS) was performed using an LTQ-XL ion trap (Thermo
Fisher Scientific) and the Xcalibur 2.0 software (Thermo Fisher
Scientific). The instrument was also tuned using a standard cali-
bration peptide (Angiotensin II, Sigma-Aldrich, St. Louis, MO) for
maximal sensitivity before running any analyses. The mass spectra
were acquired in the LTQ over a mass range of m/z 400-2000, the
ion selection threshold was 10,000 counts and the dynamic
exclusion duration was 8 s.
Raw experimental files were initially evaluated manually to
determine if the ion counts and fragmentation of each peptidewere
sufficient for further analysis. The raw data files were then pro-
cessed using PepFinder 2.0 software (Thermo Fisher Scientific). The
database used for this experiment consisted of the BG505
SOSIP.664 or GT1.1 primary sequence. Potential Cys carbamido-
methylation, Asn deamidation, and methionine (Met)/Trp/His/Cys
oxidation events were considered during the analysis. Peptide as-
signments of MS/MS spectra were validated using a confidence
score of 95%.
Size Exclusion, Cation Exchange, and Reversed-Phase High-
Performance Liquid Chromatography
Before all HPLC experiments, all samples were centrifuged for
5 min at 12,000  g to remove any large aggregates/particles that
could interfere with the analysis. Size exclusion high-performance
liquid chromatography was performed in triplicate with a Shi-
madzu HPLC system with UV absorbance detection at 220 with a
Tosoh TSKgel Ultra SW Aggregate Column and a corresponding
guard column. Experiments were performed at 25C with a mobile
phase containing 0.2 M sodium phosphate, 400 mM NaCl, and pH
7.5, and a flow rate of 0.5 mL/min was used to separate species
based on size.
Cation exchange chromatography (CEX) was also performed on
a Prominence UFLC system. Thirty microgarm of BG505 SOSIP.664
or GT1.1 trimers in formulation buffer were injected onto a TSKgel
BioAssist S column (4.6mm ID  5cm, PEEK column, Tosoh Bio-
sciences). The flow rate was set at 0.5 mL/min and the column oven
and autosampler temperatures were set at 30C and 4C, respec-
tively. Elution was monitored using the absorbance at 214 and 280
nm. Mobile phase A consisted of 10 mM NaH2PO4, pH 7.0, whereas
mobile phase B consisted of 10 mM NaH2PO4, 1 M NaCl, pH 7.0. The
mobile phase gradient consisted of 0% B (5 min), 0%-100% B
(30 min), 100% B (3 min), and 0% B (2 min).
Reversed-phase high-performance liquid chromatography (RP-
HPLC) experiments were performed on a Thermo UltiMate 3000
UHPLC system (Thermo Fisher Scientific) equipped with a diodearray detector. Thirty microgram of BG505 SOSIP.664 or GT1.1 tri-
mers in formulation buffer were injected onto a Waters ACQUITY
UPLC Protein BEH C4 column (2.1  150 mm, 1.7 mm, Waters Cor-
poration, Milford, MA). The flow rate was set at 0.2 mL/min and the
column oven and autosampler temperatures were set at 25C and
4C, respectively. Elution was monitored using the absorbance at
214 nm. Mobile phase A consisted of H2O with 0.1% TFA and mobile
phase B consisted of 0.1% TFA in 90:10 acetonitrile: H2O (v/v). The
mobile phase gradient consisted of 35% B (5 min), 35%-65% B
(30 min), 35%-95% B (4 min), 95% B (3 min), and 35% B (8 min).
Fourier-Transform Infrared Spectroscopy
Fourier-transform infrared spectroscopy (FTIR) spectroscopy
was performed using a Bruker Tensor-27 FTIR spectrometer (Bruker
Optics, Billerica, MA) equipped with a KBr beam splitter. The mer-
curic cadmium telluride detector was cooled with liquid N2 and the
interferometer was constantly purged with N2 gas. All instrument
validation tests were performed and passed before daily mea-
surements. Two hundred and fifty six scans were recorded from
4000 to 600 cm1 with a 4 cm1 resolution using a Bio-ATR cell.
Background measurements were acquired with formulation buffer
alone and subtracted from the sample spectra. Atmospheric cor-
rections, baseline corrections, and second derivative calculations
were applied using OPUS V6.5 (Bruker Optics, Billerica, MA) soft-
ware. Following Fourier self-deconvolution, between 6 and 8 peaks
were fitted to the absorbance spectrum in the Amide I region
(1700-1600 cm1) using a mixed Gaussian and Lorentzian function.
The areas of the peaks were used to determine the relative per-
centage of secondary structure components in the trimer samples.
Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was performed on the
trimer samples in triplicate using an Auto-VP capillary differential
scanning calorimeter (MicroCal/GE Health Sciences, Pittsburgh, PA)
equipped with tantalum sample and reference cells. The SOSIP.664
or GT1.1 trimers (at 0.2 mg/mL), or PBS alone, were loaded in a DSC
autosampler tray held at 4C. Scans were completed from 10C to
100C using a scanning rate of 60C/h. Reference subtraction and
concentration normalizationwere performed using the instrument
software. Tm and Tonset values were determined using Origin (Ori-
ginLab, Northampton, MA).
Fluorescence Spectroscopy
Intrinsic tryptophan fluorescence data for the SOSIP.664 and
GT1.1 gp140 trimers were collected on a Fluorescence Innovations
Plate Reader (Fluorescence Innovations Inc., Minneapolis, MN). Ten
millimeter aliquots of 0.2 mg/mL samples were analyzed in
sextuplicate in black 386-well plates. An excitation wavelength of
295 nm was used with a 315 nm filter. Samples were heated from
10C to 90C using a stepsize of 2.5C. Peak position was calculated
using Fluorescence Innovations data analysis software.
Eight-Anilino-1-naphthalene sulfonate (ANS) was used as an
extrinsic fluorescence probe in the presence of the SOSIP.664 or
GT1.1 trimers. Experiments were performed in PBS using an Agilent
Stratagene Mx3005P QPCR System. A solution containing 100 mM
ANS (generally used at 20 themolar concentration of protein) was
excited at 372 nm, and the ANS emission spectrum was collected
from 400 to 600 nm every 2 nm. The final protein concentration
used was 0.2 mg/mL.
Data Visualization Using Three-Index Empirical Phase Diagrams
Three-index empirical phase diagrams (EPDs) were constructed
as described previously17,18 to analyze the large biophysical stability
datasets generated as function of pH and temperature. Intrinsic Trp
fluorescence peak position, ANS fluorescence peak intensity, and
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gp140 proteins. All calculations were performed using the in-house
software. Each temperature and pH pair was grouped in regions
using a k-means clustering algorithm. The final definition of
structural regions was confirmed by visual assessment of the EPD
regions versus the trends observed in the biophysical data sets.
Dynamic Light Scattering
The dynamic light scattering (DLS) mode on a ZetaPALS zeta-
sizer (Brookhaven Instruments Corporation, Holtsville, NY) was
used, with quartz cuvettes that had been cleaned of any dust and
air-dried. The hydrodynamic diameters of filtered SOSIP.664 or
GT1.1 samples (at 0.5 mg/mL) were analyzed by generating an
autocorrelation decay function after centrifugation at 14,000  g
for 5 min. Ten measurements were recorded and averaged for 30 s
each. Number and intensity distributions were fitted using the
cumulant analysis algorithm provided with the instrument soft-
ware. All measurements were performed in triplicate at 25C, and
the viscosity of the solvent was 0.89 cP.
Sedimentation Velocity Analytical Ultracentrifugation
SV-AUC studies were conducted on a ProteomeLab XL-I
analytical ultracentrifuge equipped with a scanning ultraviolet-
visible optical system (Beckman Coulter, Fullerton, CA). All exper-
iments were performed at 20C with a rotor speed of 40,000 rpm
and detection at 280 nm. Samples (0.5 mg/mL of SOSIP.664 or
GT1.1) and formulation buffer alone were loaded into Beckman
charcoal-epon 2 sector cells with a 12 mm centerpiece and quartz
windows. Sednterp (Professor Thomas Laue, University of New
Hampshire) was used to calculate the partial specific volume based
on the primary sequence of the protein (around 0.73 mL/g) and the
density and viscosity of the formulation buffer. Data were analyzed
using Sedfit (Peter Schuck, NIH). A continuous c(s) distribution
fitting model was applied with 50 scans. Frictional ratio, radial in-
dependent noise, and time independent noise were also fit,
whereas the meniscus and bottom positions were set manually. A
range of 0 to 25 Svedbergs was used, after verifying that there was
no signal that sedimented outside of this range. A resolution of 300
points per distribution and a confidence level of 0.95 were used.
Microflow Imaging
Subvisible particle concentrations were assayed by microflow
imaging (MFI) using an MFI 5200 instrument (ProteinSimple, Santa
Clara, CA) equipped with a Bot1 autosampler. Before analysis, the
instrument was calibrated using 10 mm polystyrene particle stan-
dards (Thermo Fisher Scientific), and it was cleaned with filtered
water and 2% PCC-54 Detergent. BG505 SOSIP.664 samples were
measured undiluted (at 3 mg/mL) while GT1.1 trimers were diluted
10-fold into formulation buffer (final concentration of 0.05 mg/mL)
to conserve sample.
Biolayer Interferometry
BG505 SOSIP.664 and GT1.1 potencies were quantified by bio-
layer interferometry (BLI) using an Octet RED96 Bio-Layer Inter-
ferometry System (ForteBio, Menlo Park, CA). Binding experiments
were performed with Protein A Biosensors (ForteBio) in 96-well
half-area black plates. The biosensors were loaded with PGT145
antibodies at a final concentration of 1 mg/mL. Binding buffer (1
PBS, 0.1% polysorbate 20%, 0.1% BSA, pH 7.2) was used for all the
baseline and disassociation wells as well as for diluting PGT145,
SOSIP.664 or GT1.1. BG505 SOSIP.664 solutions at 300,150, 75, 37.5,
18.8, and 9.4 mg/mL were used in triplicate as standards. Samples
were all analyzed at 100mg/mL. Bindingwas performed for 300 s at
1000 rpm. Binding rates were calculated using the Octet Analysis
Software (ForteBio).Negative Staining Electron Microscopy
Trimer samples were diluted to ~0.01-0.03 mg/mL in formula-
tion buffer (see Sample Preparation) before negative staining
electron microscopy (NS-EM) analysis. Previously described pro-
cedures were followed for grid preparation, imaging, and data
analysis.16,17 A 2% (w/v) solution of uranyl formate was used as the
stain, and images were collected on an FEI Tecnai T12 electron
microscope equipped with a Tietz TemCam-F416 CMOS camera
(120 keV, 2.05 Å/pixel, ~25 e-/Å2 total dose, 1500 nm nominal
defocus).
Results
Comparative Physicochemical Characterization of BG505 SOSIP.664
and BG505 SOSIP.v4.1-GT1.1 gp140 Trimers
The primary structures of the 2 gp140 molecules (Supplemental
Fig. S1) were confirmed and compared by performing LC-MS pep-
tide mapping on BG505 SOSIP.664 (Supplemental Fig. S2) and GT1.1
gp140 proteins (Supplemental Fig. S3). The proteins were digested
using either trypsin and LysC (Supplemental Figs. S2A and S3A) or
chymotrypsin (Supplemental Figs. S2B and S3B). Chymotrypsin
digestion resulted in better sequence coverage for SOSIP.664 gp140
(~95%) than trypsin and LysC digestion (~87%). Similarly, sequence
coverage for GT1.1 was notably superior after chymotrypsin (94%
coverage) digestion, compared to trypsin and LysC (80% coverage).
Before analysis by LC-MS, the peptides were deglycosylated with
PNGase to remove the N-linked glycans. The oligosaccharide con-
tent differences between the 2 trimers were not examined here
because the glycan composition is not expected to change during
storage. This LC-MS method can be used to assess whether chem-
ical modifications of amino acid residues in the protein antigens
(e.g., Asn deamidation, Met oxidation) occur during accelerated
stability studies (see in the following).
The overall secondary and tertiary structures of the SOSIP.664
and GT1.1 gp140 trimers in solution were evaluated by FTIR and
second-derivative UV-visible spectroscopy (Fig. 1), respectively.
Small differences were observed between the second-derivative
UV-visible spectra of the 2 gp140 trimers, indicative of subtle in-
fluences of the microenvironments of their aromatic amino acids,
which likely arises from primary structure variation (Fig. 1a). FTIR
analysis revealed that both proteins had similar overall secondary
structure contents, comprising a mixture of a-helices and b-sheets,
consistent with previous structural studies19 (Figs. 1b, 1c and
Supplemental Fig. S4).
Size-based analysis of the SOSIP.664 and GT1.1 trimers was
performed using a combination of denaturing (SDS-PAGE) and
nondenaturing conditions (DLS and SV-AUC), as shown in Figure 2.
The results of the SDS-PAGE analysis were similar to those reported
previously,2 with nonreduced SOSIP.664 gp140 migrating as a sin-
gle band and the reduced sample migrating as a single gp120 band
and a poorly resolved gp41 ectodomain (gp41ecto) triplet (Fig. 2a,
left panel). Similar results were observed for GT1.1 gp140 (Fig. 2a,
right panel). The hydrodynamic diameters of the SOSIP.664 and
GT1.1 gp140 proteins in solution were determined by DLS.
Intensity-weighted cumulant analyses revealed diameters of 18.6 ±
1.6 nm and 22.9 ± 2.5 nm for SOSIP.664 and GT1.1 gp140 proteins,
respectively (Fig. 2b). One explanation for this minor discrepancy
would be the presence of small amounts of higher MW aggregates
in the GT1.1 sample. This was confirmed to be the case when the
DLS data were evaluated by an intensity-weighted mean square
displacement analysis (Supplemental Fig. S5). In addition, a greater
number of subvisible particles are present in GT1.1 samples when
analyzed byMFI (see in the following). SV-AUC was then used as an
orthogonal technique to estimate theMWs (and percent trimer) for
Figure 1. Overall secondary and tertiary structural analysis of BG505 SOSIP.664 (left) and GT1.1 (right) gp140 trimers. (a) Second-derivative UV-visible spectroscopy analysis. Error
bars represent one standard deviation from triplicate spectra. (b) Representative second-derivative analyses of FTIR spectra. (c) Summary table of secondary structure composition
of SOSIP.664 and GT1.1 as determined by FTIR. Error values represent standard deviation from triplicate measurements. See Supplemental Figure S4 for secondary structure
determination by fitting Amide I region of IR spectra to 8 peaks using a mixed Gaussian and Lorentzian function.
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trimers (Fig. 2c). The GT1.1 trimer population gave a calculated
mass of 358 ± 8 kDawith a sedimentation coefficient value of 11.9 ±
0 S, whereas the corresponding values for SOSIP.664 were 373 ± 15
kDa and 12.3 ± 0 S (Supplemental Table S1). The differences in
sedimentation coefficient values, and the estimatedmass reduction
of ~14 kDa for GT1.1, are consistent with the deletion of 7 amino
acid residues and 5 potential N-glycan sites when generating the
GT1.1 trimer from the SOSIP.664 prototype (assuming an average
amino acid MW of 110 Da and 2000 Da per glycan site). Size
exclusion chromatography was also performed on SOSIP.664
(Supplemental Fig. S6) but was found to not be as informative as
SV-AUC and was not used in analysis of GT1.1.
Reversed-phase and cation exchange high-performance liquid
chromatography (RP-HPLC, CEX-HPLC) were used to assess hydro-
phobic and charge heterogeneity, respectively, for the SOSIP.664
and GT1.1 gp140s (Fig. 3). In RP-HPLC, SOSIP.664 gp140 eluted as a
single main peak comprising over 90% of the total area, but with 2
shoulders (Fig. 3a, left panel). Threeminor peaks eluted earlier than
the main peak but collectively comprised less than 1% of the totalarea of the chromatogram. The GT1.1 RP-HPLC chromatograms
were notably different from that of SOSIP.664, in that the main
species eluted as 2 overlapping peaks (Fig. 3a, right panel). Charge
heterogeneity was evaluated by CEX-HPLC. Here, SOSIP.664 gp140
had a more heterogeneous profile than GT1.1 (Fig. 3b). Nearly all
(>99%) of the loaded SOSIP.664 protein eluted from the column
(determined by injecting sample with and without the column in
line). One main peak (at ~12.5 min) comprised ~50% of the total
peak area of the chromatograms but at least 10 individual later-
eluting peaks were also identified (Fig. 3b, left panel). The GT1.1
profile in the CEX-HPLC analysis was markedly different; while the
main peak eluted at approximately the same retention time as
SOSIP.664, no later eluting peaks were observed (Fig. 3b, right
panel). In an attempt to explain the apparent heterogeneity in the
SOSIP.664 CEX chromatographic profile, we enzymatically digested
the protein with PNGase F to remove the N-glycans from the pro-
tein (Fig. 3b and Supplemental Fig. S7). Although the SDS-PAGE
data indicated that approximately ~40 kDa of N-glycans were
removed from each SOSIP.664 monomer (Supplemental Fig. S7), no
observable changes were seen in the CEX chromatograms (Fig. 3b,
Figure 2. Molecular size analysis of BG505 SOSIP.664 (left) and GT1.1 (right) trimers under denaturing and nondenaturing conditions. (a) SDS-PAGE analysis using Coomassie blue
or silver stain. Lane 1 contains molecular weight markers, lane 2 contains nonreduced BG505 protein and lane 2 contains reduced BG505 protein. In case of nonreduced, the
predominant gp140 band is visible, whereas on reduction, gp120 and gp41 (ectodomain) are visible. (b) Dynamic light scattering data showing intensity-weighted cumulant (y-axis)
analysis for SOSIP.664 (left) and GT1.1 (right) gp140 proteins. Particle sizes (in nm) are shown along x-axis. (c) Representative SV-AUC analysis of SOSIP.664 (left) and GT1.1 (right)
with y-axis zoom shown in inset.
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analyses of PNGase F treated GT1.1 gp140 protein (Fig. 3b, right
panel and Supplemental Fig. S7).
The aforementioned analyses imply that the GT1.1 trimer is
more heterogeneous than SOSIP.664 from the perspective of hy-
drophobicity (RP-HPLC), but the converse applies to surface charge(CEX-HLPC) with SOSIP.664 being the more heterogeneous protein.
The differences between the 2 proteins could be rooted in the
amino acid sequence changes used to create the GT1.1 gp140 trimer
from SOSIP.664, including variations in post-translational modifi-
cations such as how N-glycosylation sites are utilized. In addition,
some of these differences may be due to differences in Met
Figure 3. Charge heterogeneity and hydrophobicity comparison of BG505 SOSIP.664 (left) and GT1.1 (right) gp140 proteins by different chromatographic methods. (a) Repre-
sentative RP-HPLC analyses of SOSIP.664 and GT1.1 gp140s. (b) Representative CEX-HPLC analyses of intact SOSIP.664 and GT1.1 gp140s (blue chromatogram) and PNGase F-treated
deglycosylated SOSIP.664 and GT1.1 gp140s (black chromatogram).
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results).Biophysical Stability Profile of BG505 SOSIP.664 and GT1.1 Trimers
as a Function of Temperature and pH
The conformational stability of SOSIP.664 gp140 trimers was
evaluated across a pH range of 3.0 to 9.0 and varying temperatures
by DSC, intrinsic tryptophan fluorescence peak position, and ANS
fluorescence peak intensity (Figs. 4a-4c, respectively). All 3
methods indicated that lower pH values destabilized the SOSIP.664
trimers in a temperature-dependent manner; the overall tertiary
structure of the protein molecules was affected at low pH, even at
low temperatures, consistent with data reported earlier.5 At higher
pH values (pH 6), thermal transitions were observed (Figs. 4a-4c)
with calculated Tm values between 55C and 70C (Supplemental
Fig. S8). These results are consistent with previous DSC studies.2,5
Using these biophysical stability data sets, a 3-index EPD17,18 was
constructed to better visualize and compare the temperature and
pH stability profiles of both molecules and to identify the contri-
butions of each of the 3 individual techniques (Fig. 4d, left panel).
Intrinsic tryptophan fluorescence peak position (red), extrinsic ANS
fluorescence intensity (blue), and DSC (green) were used for this
analysis, in which 5 distinct colored phases (designated as regions
I-V) were identified. Specifically, in addition to the SOSIP.664 native
state (region I), 4 structurally altered protein states (regions II-V)
were observed. Regions II and III correspond to states that arestructurally altered, to varying extents, under low pH conditions.
Region IV represents an overall structurally altered conformation,
reflecting the pH- and temperature-dependent unfolding processes
observed by DSC and intrinsic fluorescence spectroscopy. Region V
represents a more extensively structurally altered protein.
For comparison, the GT1.1 gp140 protein was evaluated using
the same biophysical methods and by EPD analysis. Overall, its
thermal and pH stability profiles were highly similar to SOSIP.664,
with region I comprising 30% of the total EPD area for both mole-
cules. The conformational stability profiles of the 2 molecules as a
function of pH and temperature, again as measured by intrinsic
tryptophan fluorescence, ANS fluorescence, and DSC, were also
similar, and no notable differences in the thermal melting tem-
perature values were identified (Figs. 4a, 6b, 6c and Supplemental
Fig. S8). As with SOSIP.664, 5 differently colored structural states
were identified in the EPD for GT1.1 (Fig. 4d, right panel).Chemical Stability Profiles of BG505 SOSIP.664 and GT1.1: Oxidative
Stress Studies
Chemical stability profiles were determined by subjecting the
SOSIP.664 and GT1.1 gp140 proteins to forced oxidation, followed
by RP-HPLC, CEX-HPLC analyses, and LC-MS peptide mapping. The
protein samples were exposed to 0%, 0.05%, and 0.5% H2O2 for 1 h at
room temperature (Fig. 5). As described previously in Figure 3, the
RP-HPLC and CEX-HPLC elution profiles of the nonstressed
SOSIP.664 and GT1.1 samples (i.e., 0% H2O2) were notably different,
Figure 4. Conformational stability of BG505 SOSIP.664 (left) and GT1.1 (right) gp140 proteins as a function of pH and temperature. (a) Tryptophan fluorescence spectroscopy peak
position in SOSIP.664 and GT1.1 as a function of temperature and pH. (b) Overall structural integrity of BG505.664 and GT1.1 as a function of temperature and pH as analyzed by DSC.
(c) ANS fluorescence intensity as a function temperature and pH. Error bars represent standard deviation from triplicate measurements. (d) Data visualization using 3-index EPD
analyses of biophysical stability data sets (a-c) for SOSIP.664 and GT1.1. See text for explanation of color scheme.
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HPLC chromatograms, GT1.1 eluted as 2 overlapping peaks (at
~24.5 and ~25.0 min), whereas only 1 peak (~24.5min) was seen forSOSIP.664 (Fig. 3a). In the presence of 0.05% H202, however, 2
closely eluting peaks were observed with SOSIP.664 (Fig. 5a). It is
therefore possible that the single peak in the unstressed SOSIP.664
Figure 5. Chemical stability profile during forced oxidation studies of BG505 SOSIP.664 and GT1.1 gp140 trimers. (a) Representative RP-HPLC analyses of (0.05% and 0.5%) H2O2
stressed SOSIP.664 and GT1.1 samples in comparison to untreated control (0% H2O2). (b) Representative CEX-HPLC analyses of (0.05% and 0.5%) H2O2 stressed SOSIP.664 and GT1.1
samples in comparison to untreated control (0% H2O2).
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on exposure to H2O2. We also saw that, in the presence of
increasing concentrations of H2O2, the polarity of both gp140
trimer samples increased, resulting in earlier elution times. In both
cases, the extent of this change in retention time was similar at the
same H2O2 concentrations. The H2O2-induced changes to the
elution profiles of the SOSIP.664 and GT1.1 gp140 trimers were also
similar in the CEX-HPLC analysis (Fig. 5b), despite the notable dif-
ferences between their elution profiles under nonstressed (control)
conditions (Fig. 3b). Thus, in the presence of H2O2, for both samples,
the area of the main peak began to decrease and shift to a later
elution volume (consistent with a more positive surface charge),
and a new peak began to emerge at ~14 min. No notable change in
total peak area was observed between samples in either chro-
matographic analysis, implying that there was no loss of protein
(i.e., no precipitation) under the test conditions.
Residues susceptible to post-translational modifications under
oxidative stress were identified by LC-MS peptidemapping. In total,
80% of the SOSIP.664 or GT1.1 primary sequences were covered in
the 0% and 0.05% H2O2-treated samples after trypsin þ LysC pro-
teolysis. This coverage includes 10 of the 12Met residues present in
both proteins (Met535 and Met540 were not identified). No peptides
were observed after proteolysis after exposure of either protein to
0.5% H2O2 (Fig. 6), which is consistent with the proteins becoming
insoluble under these stressed conditions. The relative amounts of
post-translational modifications induced by the oxidative stress in
each sample were quantified (Fig. 6c). Met oxidation (þ16 Da) wasidentified at the same 3 residues in the SOSIP.664 (Met271, Met426,
and Met475) and GT1.1 (Met271, Met426, and Met475) proteins. For
SOSIP.664, Met271 and Met426 were more prone to oxidation than
Met475 under these conditions, a pattern also seen for GT1.1 (Met271
and Met426 were more susceptible than Met475). A dehydration
reaction (indicated by a loss of 18 Da) was also detected in the
SOSIP.664 Cys228-Arg273 and GT1.1 Cys228-Arg273 peptides. It is
likely that this event arose during or after proteolysis, but this
supposition requires experimental confirmation. The amino acid
numbers, aforementioned, is based on HIV-1 HxB2 numbering
system (Supplemental Fig. S1).
Chemical Stability Profiles of BG505 SOSIP.664 and GT1.1: Elevated
Temperature and pH Stresses
We evaluated the chemical stability of the SOSIP.664 and GT1.1
gp140 trimers by increasing the temperature or pH. Under such
conditions, Asn residues can undergo a deamidation reaction
through a succinimide intermediate, which results in the formation
of iso-aspartate and aspartate residues in the protein.20 The
SOSIP.664 and GT1.1 gp140 trimers were incubated for 1week at pH
values of 7.5 or 9.0 and at temperatures of 4C or 37C, before
analysis by RP-HPLC, CEX-HPLC, and LC-MS peptide mapping. In
both chromatographic methods, no differences in the elution pro-
files of either protein were observed between the pH 7.5, 4C
(control) samples and the pH 9.0, 37C samples (Fig. 7). However,
for both trimers, the total peak areas of the pH 9.0, 37C samples
Figure 6. LC-MS peptide map analysis after forced oxidation of SOSIP.664 and GT1.1 gp140 trimers. (a) Representative UV214nm peptide map chromatograms of reduced and
trypsin þ LysC-digested SOSIP.664 after 1 h incubation with and without 0.5% v/v H2O2. Samples were evaluated in 10 mM sodium phosphate, 150 mM NaCl (pH 9.0) at room
temperature. (b) Representative UV214nm peptide map chromatograms of reduced and trypsin þ LysC-digested GT1.1 after 1 h incubation with 0%, 0.05%, or 0.5% v/v H2O2. Samples
were evaluated in 10 mM sodium phosphate, 150 mM NaCl (pH 9.0) at room temperature. The arrows indicate the location of peaks where residues (in red underlined text) are
oxidized. (c) Quantitation of oxidized Met residues in BG505 SOSIP.664 and GT1.1 samples incubated with increasing concentrations of H2O2, as determined by LC-MS peptide
mapping. Samples incubated with 0.5% H2O2 were also evaluated but could not be quantified as no peptides were observed.
N. Whitaker et al. / Journal of Pharmaceutical Sciences 108 (2019) 2264-2277 2273were ~10% lower compared to the 3 other conditions. This outcome
was consistent with protein loss during the 7-day incubation via
aggregation and precipitation. We noted that any such precipitated
proteins would probably be removed when the samples were
centrifuged before RP-HPLC analysis. The peptide chromatograms
derived from LC-MS analysis were similar for both trimers under all
the test conditions (Fig. 8). Taken together, these results indicated
that neither the SOSIP.664 nor GT1.1 gp140 trimer was highly
susceptible to Asn deamination under the test conditions of
increased pH and temperature.Stability of BG505 SOSIP.664 and GT1.1 gp140 Trimers in Common
Formulation Buffer: Agitation and Freeze Thaw Stress
An initial formulation of these vaccine antigen candidates (to
support Phase I clinical trials) needs to provide sufficient stability
for long-term storage as a frozen liquid drug product, followed by
thawing and immediate (same day) administration to patients. To
this end, we examined if the 2 molecules had similar physical
properties on freeze-thaw, not only by using the stress test
methods described previously but also by comparing the results
Figure 7. Effect of elevated temperature and pH incubation conditions on BG505 SOSIP.664 and GT1.1 gp140 trimers as measured by 2 chromatographic methods. (a) Representative
RP-HPLC analysis of stressed SOSIP.664 and GT1.1 samples. (b) Representative CEX-HPLC analysis of stressed SOSIP.664 and GT1.1 samples. Samples were stored for 7 days at pH 7.5
or 9.0 and at 4C or 37C. See Figure 3 for chromatographic profile of unstressed (control) BG505 SOSIP.664 and GT1.1 samples.
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(immunoassay and NS-EM analysis).2,5 The experiments were
performed with the standard formulation buffer (20 mM Tris, 100
mM NaCl, pH 7.5) already used for SOSIP.6645, to identify whether
any formulation changes were needed for GT1.1 to be stored as a
frozen liquid drug product.
First, the 2 gp140 trimers were subjected to agitation stress to
compare their colloidal stabilities in the formulation buffer. The
formation of subvisible particles (2-100 mm) was measured by MFI.
To conserve the more limited stocks of GT1.1 gp140 trimers during
method development, preliminary agitation studies were per-
formed using SOSIP.664, by shaking the samples for up to 72 h at
room temperature. The concentration of subvisible particles
increased until the 6 h time point, after which a decrease was seen,
possibly because larger aggregates formed and settled out.
Accordingly, the GT1.1 and SOSIP.664 gp140 trimers were then
subjected to agitation stress for up to 6 h (Fig. 9). Although the
initial GT1.1 subvisible particle concentration in the formulation
buffer was higher than for SOSIP.664, there was no notable increase
in the subvisible particle concentration after agitation stress. Thus,
the subvisible particle size distributions were similar for both
molecules, with most of the particles in the 2-5 mm size range (data
not shown).
Next, the 2 gp140 trimers, in formulation buffer, were frozen
at 80C and thawed at room temperature for 0, 1, and 5 cycles,
with their physical stability profiles monitored by SV-AUC and UV-
visible spectroscopy. No notable changes in hydrodynamic size
were observed for either protein by SV-AUC, as measured by thedistribution of sedimentation coefficient values (Fig. 10a). There
were also no changes in protein concentration after the freeze-
thaw stress, as assayed by UV-visible spectroscopy after centrifu-
gation (data not shown). Methods already established for assaying
SOSIP.664 trimer conformational stability included a BLI-based
immunoassay using the trimer-specific antibody PGT145 and NS-
EM.2,5 No notable changes in PGT145 binding were observed before
and after subjecting the SOSIP.664 or GT1.1 gp140 trimers to freeze-
thaw stress, indicating that the native-like trimer contents
remained stable (Fig. 10b). NS-EM imaging before (i.e., no freeze-
thaws) and after 3 cycles of freeze-thaw stress (Supplemental
Fig. S9) confirmed the SV-AUC and BLI findings. Thus, no non-
native Env forms were observed for either vaccine antigen.
Discussion
A detailed understanding of the structural integrity, physico-
chemical properties, and stability profiles (under both accelerated
and real-time storage conditions) is necessary for the successful
formulation development and production of stable clinical dosage
forms of any recombinant protein antigen-based vaccine candidate.
In the present study, a series of biochemical and biophysical tech-
niques were used in a developability study to compare the BG505
SOSIP.664 gp140 protein antigen to its re-engineered, gI-targeting
variant, BG505 SOSIP.v4.1-GT1.1 gp140. The stable nature of this
SOSIP.664 gp140 trimer has been determined previously,5 but no
such studies have been performed on GT1.1. Using SOSIP.664 gp140
trimer as the comparator, we demonstrated that the GT1.1 trimer
Figure 8. LC-MS peptide map analysis of BG505 SOSIP.664 and GT1.1 gp140 trimers after incubation at different temperature and pH values. (a) Representative UV214nm peptide map
chromatograms of reduced and trypsin þ LysC-digested SOSIP.664 after 7 days of incubation at 4C or 37C at 2 different pH values (7.5 or 9.0). Blue arrows indicate new peaks
observed. (b) Same conditions as panel A for GT1.1 sample.
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profiles under various environmental stresses (e.g., pH, tempera-
ture, agitation, and oxidation).
The GT1.1 gp140 trimer differs from SOSIP.664 by 18 amino acid
substitutions (resulting in the removal of 5 potential N-glycan sites)
and a 7 amino acid deletion in the V2 loop. The 2 trimers had
similar tertiary and secondary structures, as judged by second-
derivative UV spectroscopy and FTIR spectroscopy (Fig. 1). Small
differences in the UV spectroscopy data can possibly be attributed
to mutations that result in the addition or removal of aromatic
residues (i.e., A316W and Y173H). However, the hydrophobicities
and surface charges of the 2 trimers did differ (Figs. 3a and 3b).
Particularly striking is the presence of ~10 minor peaks only in the
SOSIP.664 CEX-HPLC chromatograms (Fig. 3b). Differences in the
characteristics of the extensive array of N-linked glycans present on
the 2 trimers might underpin this finding.19 More specifically, the
much simpler elution profile of the GT1.1 trimer might reflect the
absence of 5 potential N-glycan sites compared to its SOSIP.664
counterpart. Additional analyses would, however, be needed to
identity the minor peaks, such as by fraction collection followed byLC-MS. These striking chromatographic differences were not
apparent in the RP-HPLC data, which only show minor differences
in the elution profiles. An H2O2 stress test analysis suggests that the
latter differences are oxidation-dependent (Fig. 5a).
Similar physical stability profiles of the SOSIP.664 and GT1.1
gp140 trimers were noted by comparisons of their temperature and
pH behavior as measured by 3 different biophysical techniques and
assessed by data visualization tools. The 3-index EPD stability
profiles generated from the biophysical stability data sets are
similar for both trimers (Fig. 4), with no notable differences in the
defined structural regions. The only methods showing notable
differences in the structures/post-translational modifications of the
2 protein molecules were RP-HPLC and CEX-HPLC. Even so, both
proteins were similarly susceptible to oxidation and deamidation
reactions under stressed conditions (Figs. 5-8). Thus, any differ-
ences in the prestress (i.e., control) samples do not translate into
variations in whether and how chemical changes occur during
accelerated stability testing. The similar outcomes of the physico-
chemical stability tests can be indicative of comparable storage
stability profiles for the 2 SOSIP gp140 trimers under real-time
Figure 9. Subvisible (2-100 mm) particle formation (# of particle/mL) during agitation
stress studies of BG505 SOSIP.664 and GT1.1 gp140 trimers as determined by MFI.
Samples were diluted 10 before analysis and presented without correction. Error bars
represent standard deviation from triplicate measurements. Formulation buffer refers
to 20 mM Tris, 100 mM NaCl, pH 7.5.
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GT1.1 gp140 trimer is likely to be as stable as the prototypic
SOSIP.664 gp140 trimer, while noting that long-term stability
studies will be required to confirm this supposition.
The formulation, storage, and administration of vaccine antigens
for an initial phase 1 clinical trial is typically designed based on
stricter, more well-controlled conditions (e.g., administration by a
medical professional at 1 clinical site), which would not be practical
for wide distribution of commercial formulations. For example,
vaccine antigens can be stored frozen as bulk drug substances to
ensure long-term stability, and then thawed, formulated for fill as
drug products before theyaremixedwith adjuvants (“bedside”mix)
and immediately administered to a patient. To this end, the aggre-
gationpropensities and overall stabilities of the GT1.1 and SOSIP.664
gp140 trimers were assessed during agitation and freeze-thaw and
found to be comparable when both trimers were formulated in the
same simple buffer (20 mM Tris, 100 mM NaCl, pH 7.5) (Figs. 9, 10,
and Supplemental Fig. S9). This outcome was observed using the
orthogonal methods of SV-AUC and BLI immunoassay andFigure 10. Effect of freeze-thaw stress on stability profile of BG505 SOSIP.664 and GT1.1 gp14
AUC plots are representative traces from duplicate measurements with y-axis zoom shown in
bars in panel (c) represent standard deviation from triplicate measurements.confirmed by NS-EM imaging, a technique previously utilized to
evaluate trimer stability after freeze-thaw cycles.5,22
The freeze-thaw stability results are somewhat surprising given
the formulation contains 2 excipients (Tris buffer and NaCl) with
known incompatibilities with proteins during freeze-thaw stress.23
First, the pH of Tris-buffered solutions is temperature-dependent,24
which can lead to protein instability because of pH changes during
freeze-thaw cycles. Thus, when a Tris buffer is adjusted to pH 7.5 at
25C, its pH will increase to ~8.1 at 5C and to ~8.25 at 0C.25
Despite this factor, we saw no instability on freeze-thawing,
which indicates that both trimers remain physically stable under
these pH conditions. Concerns over the aforementioned
temperature-dependent pH shifts prompted preliminary stability
studies to be performed using Histidine and HEPES buffer systems,
but no notable changes in stability (and hence no improvements)
were observed in these tests (data not shown). Furthermore, the
resilience of SOSIP.664 gp140 to alkaline pHs has been observed
previously.5 A second factor is that sodium chloride is known to
concentrate during freezing, which can increase the ionic strength
of solutions.25 But again, as we saw no physical instability in the
freeze-thaw studies, we can infer that both trimers remain physi-
cally stable under these ionic strength conditions. We did perform
preliminary stability studies using 10% sucrose instead of NaCl as a
cryoprotectant and tonicifying agent, but again found no notable
changes in stability (and hence no improvements).
In summary, engineering the native-like GT1.1 gp140 trimers to
bind gl-bNAb precursors is a plausible approach to initiating the
induction of bNAbs as a HIV-1 vaccine strategy.1 However, modifi-
cations to the protein sequence (that can also lead to differences in
glycosylation profile) may impair the conformational, chemical,
and colloidal stability properties of a vaccine antigen. Each suc-
cessive iteration of the prototypic BG505 SOSIP.664 gp140 trimer
must therefore be evaluated by methodologies similar or equiva-
lent to those described here, to assess the pharmaceutical stability
of the new antigen and identify whether additional formulation
development work is required for initial clinical development using
a frozen liquid formulation. Here, we characterized both the BG505
SOSIP.664 gp140 trimer prototype and its newGT1.1 variant, using a
battery of physicochemical methods and compared their physico-
chemical stability profiles versus pH, temperature, agitation, and
freeze-thaw stresses. We conclude from this developability
assessment that the BG505 SOSIP.v4.1-GT1.1 gp140 vaccine candi-
date is similar in its overall structural stability to the SOSIP.664
gp140 trimer, from which it was engineered, from a formulation
development point of view. Hence, similar formulation conditions0 trimers as determined by (a) molecular size distribution as measured by SV-AUC. SV-
inset. (b) PGT145 antibody binding as measured by biolayer interferometry (BLI). Error
N. Whitaker et al. / Journal of Pharmaceutical Sciences 108 (2019) 2264-2277 2277and processes can be used for the existing (SOSIP.664) and new
(GT1.1) vaccine drug product candidates.5
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